바로가기
본문 바로가기
메인메뉴 바로가기
CGRL
Cancer Genomics
Research Laboratory

Clinical Research

Home > PUBLICATIONS > Clinical Research

No. Journal File
56
 Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB., Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2012 Sep;70(3):381-9.
55
 An JY, Kim E, Zakrzewska A, Yoo YD, Jang JM, Han DH, Lee MJ, Seo JW, Lee YJ, Kim TY, de Rooij DG, Kim BY, Kwon YT., UBR2 of the N-end rule pathway is required for chromosome stability via histone ubiquitylation in spermatocytes and somatic cells. PLoS One. 2012;7(5):e37414.
54
 Bae JM, Shin SH, Kwon HJ, Park SY, Kook MC, Kim YW, Cho NY, Kim N, Kim TY, Kim D, Kang GH., ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications. INTERNATIONAL JOURNAL OF CANCER. 2012 Sep 15;131(6):1323-31.
53
 Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ., ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology. 2012;83(4):218-27.
52
 Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY., Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012 Jul 6;14(4):R102.
51
 Ro J, Park S, Kim SB, Kim TY, Im YH, Rha SY, Chung JS, Moon H, Santillana S., Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. BMC CANCER. 2012 Jul 28;12(1):322.
50
 Lim KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ., Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer. Oncology. 2012;83(2):57-66.
49
 Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. Clin Transl Oncol. (Clinical & Translational Oncology). 2012 May;14(5):391-5.
48
 Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Postoperative chemoradiotherapy for gallbladder cancer. STRAHLENTHERAPIE UND ONKOLOGIE. 2012 May;188(5):388-92.
47
 Kim JW, Im SA, Kim M, Cha Y, Lee KH, Keam B, Kim MA, Han SW, Oh DY, Kim TY, Kim WH, Bang YJ., The Prognostic Significance of HER2 Positivity for Advanced Gastric Cancer Patients Undergoing First-line Modified FOLFOX-6 Regimen. Anticancer Res. 2012 Apr;32(4):1547-1553.
46
 Kim K, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW., Adjuvant Chemoradiotherapy After Curative Resection for Extrahepatic Bile Duct Cancer: A Long-term Single Center Experience. Am J Clin Oncol. 2012 Apr;35(2):136-40.
45
 Park E, Park J, Han SW, Im SA, Kim TY, Oh DY, Bang YJ, NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol. 2012 Apr;40(4):1259-66.
44
 Kim HJ, Kim HP, Yoon YK, Kim MS, Lee GS, Han SW, Im SA, Kim TY, Oh DY, Bang YJ, Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells. Anti-Cancer Drugs. 2012 Mar;23(3):288?297
43
 Lee MS, Kim HP, Kim TY, Lee JW., Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial?mesenchymal transition. Biochim. Biophys. Acta-Mol. Cell Res. 2012 Feb;1823(2):514-23.
42
 Bae JM, Cho NY, Kim TY, Kang GH., Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Cancers: Heterogeneity of Clinical Outcome Depending on Microsatellite Instability Status of Individual Tumors. Diseases of the Colon & Rectum. 2012 Feb;55(2):181-90.
41
 Kim JH, Lee JS, Kang KW, Lee HY, Han SW, Kim TY, Lee YS, Jeong JM, Lee DS., Whole-Body Distribution and Radiation Dosimetry of (68)Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. Cancer Biother Radiopharm. 2012 Feb;27(1):65-71.
40
 Kim JW, Cha Y, Kim SJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ., Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. SUPPORTIVE CARE IN CANCER. 2012 Feb;20(2):395-403.
39
 Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW., Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. JOURNAL OF NEURO-ONCOLOGY. 2012 Jan;106(2):303-13
38
 Lim JH, Kim TY, Kim WH, Park JW., CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways. Breast Cancer Res Treat. 2011 Nov;130(1):19-27.
37
 Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ., Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC CANCER. 2011 Oct 20;11:452.
이전페이지 1 2 3 4 5 6 다음페이지